Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
“We were seeking consulting in our finance function for long-term planning, financing, and reporting. We hired Patrick Nugent at FLG and he couldn’t have been a better choice. Patrick was able to provide effective frameworks and best practices, leverage his network and expertise in the industry, and engage cross-functionally. As a CFO, you have lots of choices when you hire outside resources like we did at Mission Bio, but I would definitely recommend FLG for providing talent with strong strategic-thinking, expertise, thoroughness and the ability to engage as a true partner. I wouldn’t hesitate to hire from FLG Partners again for strategic support to our Finance team.”
